Esther Rajavelu
Stock Analyst at UBS
(0.96)
# 3,913
Out of 5,163 analysts
23
Total ratings
54.55%
Success rate
-10.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $71.19 | -35.38% | 4 | Aug 12, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $20.57 | +55.57% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $313.41 | -31.40% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $21.34 | +242.08% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $9.58 | +1,037.79% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $33.19 | +5.45% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $178.55 | +27.70% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $55.05 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $22.03 | -40.99% | 1 | Nov 20, 2017 | |
| TXMD TherapeuticsMD | Initiates: Buy | $10 | $2.17 | +360.83% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $71.19
Upside: -35.38%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $20.57
Upside: +55.57%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $313.41
Upside: -31.40%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $21.34
Upside: +242.08%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $9.58
Upside: +1,037.79%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $33.19
Upside: +5.45%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $178.55
Upside: +27.70%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $55.05
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $22.03
Upside: -40.99%
TherapeuticsMD
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $2.17
Upside: +360.83%